IP Library Granted Patent US 9,101,638
Granted Patent B2
US 9,101,638 · App. 13/829,687 · Granted Aug 11, 2015

Boronic acid derivatives and therapeutic uses thereof

Inventors: Raja Reddy (San Diego, CA); Tomasz Glinka (Cupertino, CA); Maxim Totrov (San Diego, CA); Scott Hecker (Del Mar, CA)
Assignee: Rempex Pharmaceuticals, Inc.
A61K31/69A61K31/407A61K31/4196A61K31/427A61K31/546A61K45/06C07F5/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,101,638
App. No.
13/829,687
Granted
Aug 11, 2015
Kind
B2
Abstract

Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents.

Claims (66)

1. A compound having the structure of formula I:

or pharmaceutically acceptable salt thereof, wherein:

G is selected from the group consisting of —H, —NR 1 R 2 , —CH 2 N 3 , —C(O)NR′ R 2 , —CH 2 C(O)NR 1 R 2 , —CH 2 S(O) 2 NR 1 R 2 , —CH 2 —Y—Z, —CH 2 —Y—X, and —SR 3 ;

Y is selected from a group consisting of —S—, —S(O)—, —S(O) 2 —, —O—, and —NR 1 —;

R is selected from a group consisting of —H, —C 1-9 alkyl, —CR 1 R 2 OC(O)C 1-9 alkyl, —CR 1 R 2 OC(O)OC 1-9 alkyl, and

R 1 and R 2 are each independently selected from the group consisting of —H and —C 1-4 alkyl;

R 3 is —C 1-4 alkyl;

R 4 is present 1 to 3 times and each R 4 is independently selected from the group consisting of —H, —C 1-4 alkyl, —OH, —OC 1-4 alkyl, and halogen;

Z is selected from the group consisting of aryl optionally substituted with C 1-4 alkyl, amino, hydroxy, or halogen and heteroaryl optionally substituted with C 1-4 alkyl, amino, hydroxy, or halogen;

X is selected from the group consisting of —C 1-4 alkyl, —CH 2 R 5 , —CH(R 5 ) 2 , and —C(R 1 ) 3 ; and

R 5 is selected from the group consisting of a halogen, cyano, and azido group.

2. The compound of claim 1 , having the structure of (Ia):

or pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , wherein R is H.

4. The compound of claim 1 , wherein R 4 is H.

5. The compound of claim 1 , wherein G is H.

6. The compound of claim 1 , wherein G is —NH 2 .

7. The compound of claim 1 , wherein G is —C(O)NR 1 R 2 and R 1 and R 2 are each independently selected from —H and C 1-4 alkyl.

8. The compound of claim 7 , wherein R 1 is —CH 3 and R 2 is —CH 3 .

9. The compound of claim 1 , wherein G is —CH 2 C(O)NR 1 R 2 and R 1 and R 2 are each independently selected from —H and C 1-4 alkyl.

10. The compound of claim 9 , wherein R 1 is —CH 3 and R 2 is —CH 3 .

11. The compound of claim 1 , wherein R 3 is CH 3 .

12. The compound of claim 1 , wherein:

G is Cl 2- Y—Z;

Y is —S—; and

Z is selected from the group consisting of imidazole, N-methylimidazole, aminoimidazole, triazole, N-methyl triazole, aminotriazole, tetrazole, N-methyltetrazole, aminotetrazole, thiazole, aminothiazole, thiadiazole, aminothiadiazole, oxazole, oxadiazole, pyridine, pyridazine, pyrimidine and pyrazine.

13. The compound of claim 12 , wherein Z is N-methyltetrazole.

14. The compound of claim 12 , wherein Z is thiadiazole.

15. The compound of claim 12 , wherein Z is aminothiadiazole.

16. The compound of claim 1 , wherein:

G is —CH 2- Y—X; and

Y is —S—.

17. The compound of claim 16 , wherein X is CH 3 .

18. The compound of claim 16 , wherein X is CH 2 CN.

19. The compound of claim 16 , wherein X is CH 2 N 3 .

20. The compound of claim 16 , wherein X is —CH 2 F.

21. The compound of claim 16 , wherein X is —CHF 2 .

22. The compound of claim 16 , wherein X is —CF 3 .

23. The compound of claim 1 , having the structure selected from the group consisting of:

or pharmaceutically acceptable salts thereof.

24. The compound of claim 1 , having the structure selected from the group consisting of

or pharmaceutically acceptable salts thereof.

25. A compound having the structure of formula II:

or pharmaceutically acceptable salt thereof, wherein:

G is selected from the group consisting of

26. The compound of claim 25 , having the structure of:

or pharmaceutically acceptable salt thereof.

27. The compound of claim 25 , having the structure selected from the group consisting of:

or pharmaceutically acceptable salt thereof.

28. The compound of claim 25 , having the structure selected from the group consisting of:

29. The compound of claim 25 , wherein G is selected from the group consisting of

30. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable excipient.

31. The pharmaceutical composition of claim 30 , further comprising an additional medicament.

32. The composition of claim 31 , wherein the additional medicament is selected from an antibacterial agent, antifungal agent, an antiviral agent, an anti-inflammatory agent, or an anti-allergic agent.

33. The composition of claim 32 , wherein the additional medicament is a β-lactam antibacterial agent.

34. The composition of claim 33 , wherein the β-lactam is selected from Amoxicillin, Ampicillin, Pivampicillin, Hetacillin, Bacampicillin, Metampicillin, Talampicillin, Epicillin, Carbenicillin, Carindacillin, Ticarcillin, Temocillin, Azlocillin, Piperacillin, Mezlocillin, Mecillinam, Pivmecillinam, Sulbenicillin, Benzylpenicillin (G), Clometocillin, Benzathine benzylpenicillin, Procaine benzylpenicillin, Azidocillin, Penamecillin, Phenoxymethylpenicillin (V), Propicillin, Benzathine phenoxymethylpenicillin, Pheneticillin, Cloxacillin, Dicloxacillin, Flucloxacillin, Oxacillin, Meticillin, Nafcillin, Faropenem, Tomopenem, Razupenem, Cefazolin, Cefacetrile, Cefadroxil, Cefalexin, Cefaloglycin, Cefalonium, Cefaloridine, Cefalotin, Cefapirin, Cefatrizine, Cefazedone, Cefazaflur, Cefradine, Cefroxadine, Ceftezole, Cefaclor, Cefamandole, Cefminox, Cefonicid, Ceforanide, Cefotiam, Cefprozil, Cefbuperazone, Cefuroxime, Cefuzonam, Cefoxitin, Cefotetan, Cefmetazole, Loracarbef, Cefixime, Ceftriaxone, Cefcapene, Cefdaloxime, Cefdinir, Cefditoren, Cefetamet, Cefmenoxime, Cefodizime, Cefoperazone, Cefotaxime, Cefpimizole, Cefpiramide, Cefpodoxime, Cefsulodin, Cefteram, Ceftibuten, Ceftiolene, Ceftizoxime, Flomoxef, Latamoxef, Cefepime, Cefozopran, Cefpirome, Cefquinome, Ceftobiprole, Ceftaroline, CXA-101, RWJ-54428, MC-04,546, ME1036, Ceftiofur, Cefquinome, Cefovecin, RWJ-442831, RW1-333441, or RWJ-333442.

35. The composition of claim 33 , wherein the β-lactam is selected from Ceftazidime, Biapenem, Doripenem, Ertapenem, Imipenem, Meropenem, or Panipenem.

36. The composition of claim 33 , wherein the β-lactam is selected from Aztreonam, Tigemonam, BAL30072, SYN 2416, or Carumonam.

37. A method of treating a bacterial infection, comprising administering to a subject in need thereof, a compound according to claim 1 and a B-lactam antibacterial agent.

38. The method of claim 37 , wherein the β-lactam is selected from Amoxicillin, Ampicillin, Pivampicillin, Hetacillin, Bacampicillin, Metampicillin, Talampicillin, Epicillin, Carbenicillin, Carindacillin, Ticarcillin, Temocillin, Azlocillin, Piperacillin, Mezlocillin, Mecillinam, Pivmecillinam, Sulbenicillin, Benzylpenicillin (G), Clometocillin, Benzathine benzylpenicillin, Procaine benzylpenicillin, Azidocillin, Penamecillin, Phenoxymethylpenicillin (V), Propicillin, Benzathine phenoxymethylpenicillin, Pheneticillin, Cloxacillin, Dicloxacillin, Flucloxacillin, Oxacillin, Meticillin, Nafcillin, Faropenem, Tomopenem, Razupenem, Cefazolin, Cefacetrile, Cefadroxil, Cefalexin, Cefaloglycin, Cefalonium, Cefaloridine, Cefalotin, Cefapirin, Cefatrizine, Cefazedone, Cefazaflur, Cefradine, Cefroxadine, Ceftezole, Cefaclor, Cefamandole, Cefminox, Cefonicid, Ceforanide, Cefotiam, Cefprozil, Cefbuperazone, Cefuroxime, Cefuzonam, Cefoxitin, Cefotetan, Cefmetazole, Loracarbef, Cefixime, Ceftriaxone, Cefcapene, Cefdaloxime, Cefdinir, Cefditoren, Cefetamet, Cefmenoxime, Cefodizime, Cefoperazone, Cefotaxime, Cefpimizole, Cefpiramide, Cefpodoxime, Cefsulodin, Cefteram, Ceftibuten, Ceftiolene, Ceftizoxime, Flomoxef, Latamoxef, Cefepime, Cefozopran, Cefpirome, Cefquinome, Ceftobiprole, Ceftaroline, CXA-101, RWJ-54428, MC-04,546, ME1036, Ceftiofur, Cefquinome, Cefovecin, RWJ-442831, RWJ-333441, or RWJ-333442.

39. The method of claim 37 , wherein the β-lactam is selected from Ceftazidime, Biapenem, Doripenem, Ertapenem, Imipenem, Meropenem, or Panipenem.

40. The method of claim 37 , wherein the β-lactam is selected from Aztreonam, Tigemonam, BAL30072, SYN 2416, or Carumonam.

41. The method of claim 37 , wherein the subject is a mammal.

42. The method of claim 41 , wherein the mammal is a human.

43. The method of claim 37 , wherein the infection comprises a bacteria selected from Pseudomonas acidovorans, Pseudomonas alcaligenes, Pseudomonas putida, Burkholderia cepacia, Aeromonas hydrophilia, Francisella tularensis, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Providencia alcalifaciens, Providencia rettgeri, Providencia stuartii, Acinetobacter baumannii, Bordetella pertussis, Bordetella parapertussis, Bordetella bronchiseptica, Haemophilus ducreyi, Pasteurella multocida, Pasteurella haemolytica, Branhamella catarrhalis, Borrelia burgdorferi, Kingella, Gardnerella vaginalis, Bacteroides distasonis, Bacteroides 3452A homology group, Clostridium difficile, Mycobacterium tuberculosis, Mycobacterium avium, Mycobacterium intracellulare, Mycobacterium leprae, Corynebacterium diphtheriae, Corynebacterium ulcerans, Streptococcus pneumoniae, Streptococcus agalactiae, Streptococcus pyogenes, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus intermedius, Staphylococcus hyicus subsp. hyicus, Staphylococcus haemolyticus, Staphylococcus hominis , or Staphylococcus saccharolyticus.

44. The method of claim 37 , wherein the infection comprises a bacteria selected from Pseudomonas aeruginosa, Pseudomonas fluorescens, Stenotrophomonas maltophilia, Escherichia coli, Citrobacter freundii, Salmonella typhimurium, Salmonella typhi, Salmonella paratyphi, Salmonella enteritidis, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Enterobacter cloacae, Enterobacter aerogenes, Klebsiella pneumoniae, Klebsiella oxytoca, Serratia marcescens, Acinetobacter calcoaceticus, Acinetobacter haemolyticus, Yersinia enterocolitica, Yersinia pestis, Yersinia pseudotuberculosis, Yersinia intermedia, Haemophilus influenzae, Haemophilus parainfluenzae, Haemophilus haemolyticus, Haemophilus parahaemolyticus, Helicobacter pylori, Campylobacter fetus, Campylobacter jejuni, Campylobacter coli, Vibrio cholerae, Vibrio parahaemolyticus, Legionella pneumophila, Listeria monocytogenes, Neisseria gonorrhoeae, Neisseria meningitidis, Moraxella, Bacteroides fragilis, Bacteroides vulgatus, Bacteroides ovalus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides eggerthii , or Bacteroides splanchnicus.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2018
From: REMPEX PHARMACEUTICALS, INC.
To: THE MEDICINES COMPANY (SAN DIEGO), LLC
Reel/Frame 046932/0260 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 3, 2013
From: REDDY, RAJA; GLINKA, TOMASZ; TOTROV, MAXIM; HECKER, SCOTT
To: REMPEX PHARMACEUTICALS, INC.
Reel/Frame 031709/0147 →
Continuity (2)
Provisional Application 61749210 · Jan 4, 2013
Related Publication 20140194382A1 · Jul 10, 2014